Zheng J, Xie Y, Ren L, Qi L, Wu L, Pan X et al (2021) GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimers disease
Benefits (Research Focus) Triple receptor agonism studied for simultaneous activation of GLP-1, GIP, and glucagon receptors Body composition research investigated for fat-mass and lean-mass partitioning in DIO rodent models Glycemic endpoints examined for fasting glucose and HbA1c parameters in T2D research models Energy expenditure explored for glucagon-mediated thermogenic effects unique among incretin analogs Long-acting profile C20 fatty diacid albumin-binding chemistry for extended half-life research What Researchers Look At Receptor binding affinity and selectivity across GLP-1R / GIPR / GCGR cAMP activation curves in cell lines expressing each receptor subtype Food intake, body weight, and adipose-tissue change in DIO rodent models Hepatic steatosis, ALT/AST, and liver fat fraction endpoints Comparative pharmacology versus semaglutide, tirzepatide, and other incretin analogs Quick Specs Form: Lyophilized white powder Net Peptide Content: 10 mg per vial Quantity: 1 vial Appearance: White to off-white lyophilizate Reconstitution: Bacteriostatic or sterile water (added by the end researcher) Purity: 99% by HPLC Identity: MS-verified (per COA) Storage: Protect from light Identity Basics Compound: Retatrutide Synonyms: LY3437943
Works to aid appetite regulation, promote balanced blood sugar levels, and support weight managementhelping you support overall vitality
Better Business Bureau
Both semaglutide (Wegovy) and tirzepatide (Zepbound) are recommended by NICE within specific clinical criteria, which typically include a BMI of 35 kg/m or above alongside at least one weight-related comorbidity, or a BMI of 30 kg/m or above in certain higher-risk groups, and access is generally through specialist NHS weight management services
Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes
